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Abstract
High circulating cholesterol is associated with hypercholesterolemia, atherosclerosis, and stroke. However, the
relation between cholesterol and tumorigenesis/metastasis is controversial. The proprotein convertase subtilisin/
kexin type 9 (PCSK9) regulates low-density lipoprotein cholesterol homeostasis by targeting the low-density lipo-
protein receptor (LDLR) for degradation. PCSK9 is mostly expressed in liver, which is one of the most common sites
for metastatic disease. To reveal the function of PCSK9 and also evaluate the impact of cholesterol in liver metas-
tasis development, B16F1 melanoma cells were injected into wild-type (WT) and Pcsk9−/− mice to induce liver
metastasis. On chow diet, Pcsk9−/− mice harbored two-fold less liver metastases than WT mice. This decrease
is related to low cholesterol levels in Pcsk9−/− mice, as the protection was lost after normalizing Pcsk9−/− choles-
terol levels by a 2-week high cholesterol diet. Furthermore, a prolongation of this diet strongly increased metastasis
in both genotypes, suggesting that high cholesterol levels promote metastatic progression. The protective effect of
the PCSK9 deficiency is also associated with increased apoptosis in liver stroma and metastases. Tumor necrosis
factor–α (TNFα) mRNA and protein were, respectively, higher in liver stroma and plasma of injected mice, likely
increasing the apoptotic TNFα signaling. Furthermore, the anti-apoptotic factor B-cell lymphoma 2 was down-
regulated. TNFα regulation is LDLR-independent, as its mRNA level was similarly upregulated in mice lacking both
PCSK9 and LDLR. Our findings show that PCSK9 deficiency reduces liver metastasis by its ability to lower choles-
terol levels and by possibly enhancing TNFα-mediated apoptosis.
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Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to a
family of secretory serine proteases, named proprotein convertases
(PCs) [1]. Gain-of-function mutations in the PCSK9 gene are asso-
ciated with familial hypercholesterolemia [2]. In contrast, loss-of-
function mutations are associated with reduced low-density lipoprotein
cholesterol (LDLc) and lower risk of coronary artery disease [3,4].
PCSK9 regulates cholesterol homeostasis by controlling the protein
levels of the low-density lipoprotein receptor (LDLR), which uptakes
low-density lipoprotein particles into cells. Binding of PCSK9 to
cell surface LDLR promotes its internalization and degradation in
endosomal/lysosomal compartments [5–7]. PCSK9 inhibition therefore
emerged as a promising therapy to treat hypercholesterolemia [8].
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Beyond its role in maintaining cholesterol homeostasis, PCSK9 is
implicated in numerous biologic processes. Microarray studies re-
vealed that PCSK9 overexpression leads to the dysregulation of many
pathways, including cell cycle, apoptosis, and inflammatory and stress
responses [9,10]. In vivo studies also suggest that PCSK9 is implicated
in these processes [11,12]. Following partial hepatectomy, Pcsk9−/−
mice exhibit a delay in hepatocyte proliferation and enhanced apop-
tosis, which can be rescued by feeding mice a high cholesterol diet
(HCD) [11]. Moreover, Pcsk9−/−mice exhibit hypoinsulinemia, hyper-
glycemia, and glucose intolerance [12].
Because biologic processes such as cell cycle and proliferation are
modified in cancer, we suspected that PCSK9 could regulate tumori-
genesis/metastasis. Furthermore, as PCSK9 inhibitors or silencers
may soon be available on the market [8], it was of interest to evaluate
the safety of PCSK9 deficiency in relation to cancer/metastasis. So far,
only two human studies examined a possible link between PCSK9
polymorphisms known to lower circulating LDLc levels and the risk
of cancer [13,14]. Although one of the studies established a statisti-
cally valid association between low circulating LDLc and increased
risk of cancer [13], neither study could associate heterozygote PCSK9
loss-of-function variants (R46L, −15% LDLc; Y142X or C679X,
−29% LDLc) with a higher cancer incidence. Using our PCSK9
knockout mouse models [11,15], we directly addressed the function
of PCSK9 in cancer development.
In this study, upon injection of B16F1 mouse melanoma cells
into spleen, which preferentially metastasize to the liver [16], Pcsk9−/−
mice developed less hepatic metastatic melanomas. This protective
effect of the PCSK9 deficiency was abrogated by increased total
cholesterol (TC) levels following an HCD. We also showed that
Pcsk9−/− mice exhibited increased liver stromal and tumoral apop-
tosis, likely because of the activation of the tumor necrosis factor–α
(TNFα) pathway.
Materials and Methods
Cell Culture, Plasmids, Transfection, and
Western Blot Analysis
Human embryonic kidney 293 (HEK293) cells and B16F1 cells
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen,
Burlington, Canada) and HepG2 cells in modified Eagle’s medium
(Invitrogen) supplemented with 10% FBS (Invitrogen). All cells were
maintained at 37°C under 5% CO2.
The cDNA of mouse or human wild-type (WT) PCSK9 and its
mutant form, PCSK9D374Y, were cloned into the pIRES2-EGFP vector
(Clontech, Mountain View, CA), as described previously [1]. Non-
targeting shRNA (NTsh) and PCSK9-targeting shRNA (PC9sh) con-
structs, generation of lentiviral particles, and transductions of HepG2
cells to obtain stable pools were described previously [17]. Human
HEK293 and HepG2 cells and mouse B16F1 cells were transfected
using Effectene (Qiagen, Toronto, Canada), Fugene HD (Roche,
Laval, Canada), and Lipofectamine 2000 (Invitrogen) reagents, respec-
tively. Stable B16F1 and HepG2 cells overexpressing either WT or
PCSK9D374Y were obtained upon puromycin selection.
HEK293 cells were transfected with the vector pIRES2-EGFP empty
or encoding V5-tagged PCSK9 or PCSK9D374Y, washed at 24 hours
post-transfection, and then incubated with serum-free medium for
another 24 hours. Media were then collected or transferred onto
B16F1 or HepG2 cells for 12 hours. Media and cell lysate proteins were
separated by 8% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, blotted onto polyvinylidene difluoride (PVDF) membranes,
and incubated with a polyclonal human PCSK9 (1:2000) [7], human
or mouse LDLR (1:1000; R&D Systems, Toronto, Canada), β-actin
(1:5000; Sigma, Toronto, Canada), or HRP-conjugated V5 (1:10,000;
Sigma) antibodies (Abs).
RNA Isolation, Quantitative Polymerase Chain Reaction, and
Quantitative Polymerase Chain Reaction Array
Liver samples were dissected from the right medial lobe. For meta-
static livers, the absence of tumor contamination in the adjacent
normal tissue samples (stroma) was verified by quantitative polymerase
chain reaction (qPCR) analysis of transcripts for tyrosinase, an abun-
dant enzyme implicated in melanin synthesis in B16-derived tumors
(FigureW1). All cell and tissue samples were submitted to RNA extrac-
tion using TRIzol reagent (Invitrogen). cDNA were then prepared as
described previously [18]. All qPCRs were carried out in a final vol-
ume of 10 μl using the SYBER Green Supermaster (Quanta Bio-
sciences, Gaithersburg, MD) following the manufacturer’s protocol.
Liver WT and Pcsk9−/− stromal cDNA were also submitted to a mouse
apoptosis qPCR array (SuperArray, Frederick, MD) according to the
manufacturer’s protocol. Specific primers were used for the amplifi-
cation of the following cDNAs: furin [18], PCSK9 [11], 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase (forward: 5′-
GTACGGAGAAAGCACTGCTGAA; reverse: 5′-TGACTGCCAG-
AATCTGCATGTC), LDLR (forward: 5′-GTATGAGGTTCCTG-
TCCATC; reverse: 5′-CCTCTGTGGTCTTCTGGTAG), TNFα
(forward: 5′-CCAGAACTCCAGGCGGTGCC; reverse: 5′-CTGAT-
GAGAGGGAGGCCATTTGGGA), TNFα receptor 1 (TNFR1;
forward: 5′-CCACCCGCAACGTCCTGACA; reverse: 5′-AGGCA-
CGCCATCCACCACAG), B-cell lymphoma 2 (Bcl-2; forward: 5′-
TGAACCGGCATCTGCACACCTG; reverse: 5′-AAACAGAG-
GTCGCATGCTGGGG), and TNF receptor–associated factor 2
(TRAF2; forward: 5′-TGCCCGCAGAGAGGTGGAGAG; reverse:
5′-CCTTCTCGCTGAGGCGGACC). Simultaneously, cDNA for
TATAA-box binding protein (TBP) were amplified for normali-
zation (forward: 5′-CCTAGTGGAGGTGCCTTGGA; reverse:
5′-GGTTGCCACCTGAAGTCACA).
Animals and Experimental Metastasis Assay
ApcMin/+ mice were obtained from the Jackson Laboratory (Bar
Harbor, ME) [19]. Generation of Pcsk9−/− mice that lack the proxi-
mal promoter and first exon of the Pcsk9 gene was described previ-
ously [11], as well as that of mice lacking LDLR [20] or both
LDLR and PCSK9 [15]. All mice were on the C57BL/6J background.
The following procedures were approved by the Animal Care Com-
mittee of the Institut de Recherches Cliniques de Montreal. Six- to
eight-week-old female mice were anesthetized with 2% isoflurane
inhalation. B16F1 cells were suspended in phosphate-buffered saline
(PBS; 105 cells/100 μl) and injected directly into spleen, and mice were
sacrificed 12 days later. Mice were fed either a chow diet (2018 Teklad
Global) or an HCD (TD.08464 Harlan Teklad) for 14 or 26 days
before sacrifice day. Livers were then removed to be photographed.
Tumor and liver areas were quantified by image software Northern
Eclipse, and tumor density was calculated as the ratio of tumor area
and total liver area.
B16F1 Cell Adhesion Assay
Primary hepatocytes were prepared using 10- to 12-week-old
mice and the two-step collagenase perfusion method, as described
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previously [21]. Hepatocytes were seeded in a 24-well plate (105/well)
coated with 0.5 mg/ml fibronectin (Sigma-Aldrich). Only the wells
in which a perfect cell monolayer was formed were used for adhesion
assay. B16F1 cells (3 × 106) were labeled with 30 μCi of 3H-thymidine
(PerkinElmer Life Sciences, Toronto, Canada) for 24 hours. Cells
were then trypsinized, washed with PBS, and suspended in 10 ml of
Dulbecco’s modified Eagle’s medium containing 10% FBS or 10%
lipoprotein-deficient serum (LPDS; Biomedical Technologies, Stoughton,
MA). 3H-labeled B16F1 cells (104 cells in 100 μl) were then added on
hepatocyte monolayers, which were pre-incubated for 3 hours with
FBS- or LPDS-containing media. After 1-hour adhesion, media were
removed. Cells were washed and incubated with cold 10% TCA for
30 minutes, lysed in a 0.5 M NaOH/0.1% sodium dodecyl sulfate
solution, and finally submitted to 3H radioactivity counting.
In Vitro Cell Growth
Cells (104/well) were distributed in 96-well plates and subjected
to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) cell proliferation assay
(Promega, Madison, WI) at multiple time points. Optical absorption
was read at 490 nm using a Vmax microplate reader (Molecular
Devices, Sunnyvale, CA).
Apoptosis Assay
B16F1 and HepG2 cells were grown either in the absence or
presence of 1 μM staurosporine (Sigma) for 12 hours. Cells were
collected in reaction buffer [20 mM PIPES (pH 7.2), 100 mM
NaCl, 1 mM EDTA, 0.1% CHAPS, and 10% sucrose]. Liver, hepatic
tumors, and adjacent stromal tissues were dissected and homoge-
nized (Polytron and Brinkmann Instruments, Mississauga, Canada)
in reaction buffer. Cell lysis was completed by two cycles of 10 minutes
freezing and thawing. Caspase-3 activity was then measured at 37°C in
80 μg of proteins using 30 μg of the caspase-3 fluorogenic substrate,
acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Calbiochem,
Mississauga, Canada). The fluorescence generated by free amido-
4-methylcoumarin was detected with a SpectraMAX GEMINI EM
microplate spectrofluorometer (Molecular Devices; excitation, 380 nm;
emission, 460 nm), and caspase-3 activity was expressed as the released
relative fluoresce units per minute.
Apoptosis in liver paraffin sections was assessed using In Situ Cell
Death Detection Kit, POD according to the manufacturer’s instruc-
tions (Roche).
Plasma Measurement
Plasma TC was measured using the Infinity Kit (Thermo Scien-
tific, Ottawa, Canada). Specific ELISA kits were used to measure
mouse plasma PCSK9 (CircuLex, Toronto, Canada) and TNFα (Cell
Signaling Technology, Pickering, Canada), according to the manu-
facturer’s recommendations.
Results
PCSK9 Expression Is Higher in Intestinal Tumors than in
Adjacent Normal Tissues
To probe the possible involvement of PCSK9 in cancer devel-
opment, we looked at its expression in various cancers reported in
the ONCOMINE database (http://www.oncomine.org). PCSK9
expression was upregulated by 1.2- to 2.8-fold in all cancer types
assessed (Figure W2), except in the steroid-dependent breast and
prostate carcinomas, where PCSK9 was downregulated by 40% to
50%. We completed these data with the analysis of tumors in intes-
tine, one of the major sites of PCSK9 expression [1]. At 4 months of
age, the ApcMin/+ mice, which constitute a colorectal cancer model,
spontaneously develop along their small intestine about one tumor
per centimeter [18,19]. A representative hematoxylin and eosin–
stained tumor section is shown in Figure 1. qPCR analysis of ApcMin/+
tumors and their adjacent normal tissues demonstrated that PCSK9
mRNA was 3.1-fold higher in tumors (Figure 1). This up-regulation
was likely due to the transcriptional activation of the cholestero-
genic pathway by the sterol response element binding protein 2, as
LDLR and HMG-CoA reductase mRNA levels were also increased
(two-fold). Thus, PCSK9 was upregulated in intestinal tumors as in
most cancers.
Development of Hepatic Tumors Is Reduced in Pcsk9−/− Mice
The liver is the major site of PCSK9 expression with ∼10-fold
higher levels of mRNA than in colon and intestine [1]. To investi-
gate the in vivo role of PCSK9 in hepatic cancer development, we
Figure 1. PCSK9 is upregulated in intestinal tumors. An Apcmin/+ mouse small intestine section stained with hematoxylin and eosin
shows the structure of an intestinal tumor (T) and its adjacent normal tissue (N). Expression of PCSK9, LDLR, and HMG-CoA reductase
was assessed by qPCR in 18 couples of tumors and their adjacent normal tissues collected from three Apcmin/+ mice of 4 months of
age. mRNA levels in tumors were normalized to that of their respective adjacent stromal tissues, which was set to 1. Error bars repre-
sent SEM. *P < .05; **P < .01 (Student’s t test).
1124 The Loss of PCSK9 Reduces Liver Metastasis Sun et al. Neoplasia Vol. 14, No. 12, 2012
used a metastasis model, in which B16F1 mouse melanoma cells are
injected into the spleen of C57BL/6 mice. Metastases were formed
on the surface of the liver and were easily identified after 12 days
because of the black melanin pigment they synthesize (Figure 2A ).
When 200,000 cells were injected into WT and Pcsk9−/− mice fed
a regular chow diet, Pcsk9−/− mice harbored two-fold less hepatic
melanoma foci than WT mice (Figure 2, A and B). To assess whether
the protective effect of PCSK9 deficiency was due to its associated
hypocholesterolemia (TC = 77 mg/dl versus 112 mg/dl for WT
mice; Figure 2C ) [11,22], we fed mice an HCD (0.4% cholesterol)
for 14 days before euthanasia. Although this diet did not affect TC
levels in WT mice, it brought Pcsk9−/− mice TC to 102 mg/dl, similar
to 114 mg/dl in WT mice (Figure 2C ). In parallel to TC levels, tumor
density rose in Pcsk9−/− mice from 13% on a chow diet to 20% on an
HCD but did not change in WT mice (27% versus 25%; Figure 2, A
and B ). When mice were fed an HCD for 26 days before euthanasia,
TC levels were increased by 1.5- and 1.8-fold, and tumor density rose
by ∼2- and ∼4-fold, in WT and Pcsk9−/− mice, respectively (Figure 2).
In addition, mice fed a 26-day HCD exhibited tumors with a very high
degree of necrosis.
The loss of statistical significance between the WT and Pcsk9−/−
tumor densities when mice were fed an HCD indicates that the pro-
tective effect of PCSK9 deficiency mainly resides in its ability to
lower circulating cholesterol levels. Furthermore, our data show that
a high dietary cholesterol intake significantly enhances the develop-
ment of liver metastases.
B16F1 Cells Do Not Express PCSK9 and Their LDLR Levels
Are Not Sensitive to Exogenous PCSK9
To understand the underlying molecular mechanism(s) behind
the protective role of PCSK9 deficiency on liver metastases develop-
ment, we analyzed by qPCR the mRNA expression of PCSK9 and
other members of the PC family in B16F1 cells (Figures 3A and
W3). Importantly, although PCSK9 expression was abundant in
the human hepatocellular carcinoma HepG2 cells, it was extremely
low in B16F1 cells and undetectable in B16F1 cell–derived hepatic
tumors collected 12 days post-injection (Figure 3A). This suggests that
the higher metastasis observed in WT mice is due to liver PCSK9 that
modulates the host microenvironment, rather than to PCSK9 from
B16F1 cells. Thus, B16F1 tumor cells constitute a good model to study
the exclusive impact of host PCSK9 on metastasis.
To mimic the in vivo paracrine/endocrine influence of host PCSK9,
we incubated B16F1 cells overnight with media from HEK293 cells
expressing V5-tagged mouse PCSK9, human PCSK9, or its most
potent gain-of-function mutant PCSK9D374Y [23,24] and analyzed
PCSK9-enhanced LDLR degradation by Western blot analysis. Sur-
prisingly, none of the three PCSK9 forms were able to degrade the
LDLR in B16F1 cells. In contrast, the same media incubated with
Figure 2. The loss of PCSK9 decreases hepatic metastasis in a cholesterol-dependent manner. (A) Mice were fed a chow diet or an HCD
for 14 or 26 days before euthanasia and were injected with B16F1 cells 12 days before euthanasia. Livers were dissected and repre-
sentative livers and liver sections are shown. Insets emphasize the accumulation of lipid droplets in the livers of mice fed an HCD for
26 days. (B) Tumor density (area of tumors/total area of liver) was evaluated in 12 to 18 mice per genotype and per condition. (C) Total
cholesterol levels were measured in plasma collected on day of sacrifice. Error bars represent SEM. *P < .05, **P < .01, ***P < .001
(Student’s t test).
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HepG2 cells can trigger LDLR degradation (Figure 3). Although
exogenous PCSK9 did not affect LDLR levels, it likely bound the cell
surface LDLR of B16F1 cells, as V5-immunoreactive species were
detected in cell lysates, especially with PCSK9D374Y (Figure 3B), known
to exhibit a >10-fold better binding to the LDLR [24].
Metastasis is a complex multistep process including cell extravasa-
tion from the primary tumor, intravasation and adhesion in distant
organs, and proliferation to form secondary tumors [25]. In our exper-
imental model, the final metastatic volume was shown to depend on
tumor cell implantation and focal growth of metastases [26]. We thus
decided to focus on the function of PCSK9 in cancer cell adhesion
and proliferation.
B16F1 Cell Adhesion to Primary Hepatocytes Increases in the
Absence of PCSK9
The role of PCSK9 in cell adhesion was assessed by measuring the
attachment of B16F1 cells to primary hepatocytes (Figure 4). B16F1
cells were radioactively labeled by 3H-thymidine incorporation and
then added directly onto a monolayer of mouse primary hepato-
cytes. After 1-hour incubation in a cholesterol-rich (10% FBS) or
cholesterol-deficient (10% LPDS) medium, cells were washed and
lysed, and the radioactivity was counted. In 10% FBS, 41% more
B16F1 cells adhered onto Pcsk9−/− versus WT hepatocytes. This dif-
ferent capacity of adhesion is probably caused by a cell surface pro-
tein other than LDLR, as the same adhesion difference was observed
between Ldlr−/− and Ldlr−/−Pcsk9−/− (dKO) hepatocytes. In contrast,
B16F1 adhesion was insensitive to the genotype of hepatocytes in
LPDS medium (Figure 4).
Because Pcsk9−/− mice developed less metastasis than WT mice, it
was surprising to observe that Pcsk9−/− primary hepatocytes bound
more B16F1 cells than WT hepatocytes in FBS media. This suggests
that, in vivo, hypocholesterolemia blunts the adhesion potential of
B16F1 cells to liver and reduces metastasis through a different mech-
anism than a change in adhesion.
PCSK9 Does Not Modulate the Growth and Apoptosis of
B16F1 Cells but Affects Those of Liver Cells
We then examined the impact of PCSK9 on B16F1 cell prolifer-
ation. We first incubated B16F1 cells with or without 5 μg/ml of
purified human PCSK9 [27] and measured cell growth using an
MTS assay. Similar growth curves were obtained (Figure 5A), indi-
cating that host PCSK9 should not affect B16F1 cell proliferation
in vivo. To further challenge B16F1 cell growth, we grew cells
stably expressing an empty vector (pIR), human PCSK9, or its
gain-of-function mutant PCSK9D374Y in 10% FBS or 10% LPDS
medium (Figure 5B). Cell proliferation was drastically reduced in
the lipoprotein-deficient medium, indicating that B16F1 cell growth
strongly depends on cholesterol. However, growth curves were not
affected by PCSK9 overexpression, suggesting that B16F1 cell prolif-
eration is not affected in vivo by PCSK9. Finally, as a control, we
examined the growth of HepG2 cells whose LDLR levels are sensitive
to exogenous PCSK9 (Figure 3B). HepG2 cells that stably express
human PCSK9, NTsh, or antisense PC9sh [17] were grown in 10%
FBS media (Figure 5C ). Although higher PCSK9 levels did not affect
growth, as observed for B16F1 cells, knocking down PCSK9 signifi-
cantly reduced HepG2 cell growth.
The slower growth of HepG2 cells lacking PCSK9 may be due to
increased cell death. Accordingly, cellular apoptosis was estimated by
measuring caspase-3 enzymatic activity at basal levels and in the pres-
ence of 1 μM staurosporine, an apoptosis inducer. HepG2 cells lack-
ing PCSK9 (PC9sh) exhibited 170% to 200% higher caspase-3
Figure 3. B16F1 cells do not express PCSK9 and their LDLR is
insensitive to exogenous PCSK9. (A) PCSK9 expression was quan-
tified by qPCR in HepG2 cells, B16F1 cells, and B16F1 cell–derived
liver tumors (n = 3 for each). As a control, expression of the ubiqui-
tous furin was also quantified. Error bars represent SEM. (B) Media
of HEK293 cells that express the empty pIRES2-EGFP vector, mouse
(mWT) or human (hWT) WT PCSK9, or human gain-of-function
PCSK9D374Y (hD347Y), all containing a C-terminal V5 tag, were col-
lected and transferred onto B16F1 or HepG2 cells for 12 hours.
HEK293 cell media and B16F1 and HepG2 cell lysateswere analyzed
by Western blot analysis using a V5 Ab to reveal PCSK9 and mouse
or human LDLR and β-actin Abs. Band intensities were quantified
by ImageJ software and LDLR intensities were first normalized to
that of β-actin (LDLR/act). Ratios were then normalized to that of
the empty vector that was set to 1. A representative experiment of
three is shown.
Figure 4. The adhesion of B16F1 cells to primary hepatocytes is
regulated by PCSK9 and cholesterol. B16F1 cells were incubated
with 3H-thymidine for 24 hours and then added onto WT, Pcsk9−/−,
Ldlr−/−, and Ldlr−/−Pcsk9−/− primary hepatocytes, which were pre-
incubated in media containing either 10% FBS or 10% LPDS for
3 hours. After 1 hour of incubation, unadhered B16F1 cells were
washed out, the remaining cells were lysed, and radioactivity in
the total lysates was counted. The error bars indicate SEM of four
independent experiments. *P < .05; (Student’s t test).
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activity versus control HepG2 cells (NTsh; Figure 5D). Similarly,
caspase-3 activity in Pcsk9−/− primary hepatocytes was 170% higher
than in WT ones (Figure 5D). In contrast, B16F1 cells pre-incubated
with or without 5 μg/ml of purified PCSK9 for 24 hours exhibited
similar caspase-3 activity, in the absence or presence of staurosporine
(Figure 5D). Thus, in vitro, only the absence of PCSK9 had an effect on
HepG2 cell proliferation, likely through increased apoptosis, whereas
PCSK9 had no major effect on B16F1 cell proliferation or apoptosis.
In vivo, basal caspase-3 activities in WT and Pcsk9−/− livers were sim-
ilar. However, like in HepG2 cells, injected livers lacking PCSK9 exhib-
ited 50% higher caspase-3 activities, both in B16F1 cell–derived liver
tumors and their adjacent stromal tissues (Figure 5E ). This was con-
firmed by terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay on corresponding liver sections. In tumoral regions, the
labeling was highly concentrated in the center of the tumor, making any
quantification of the number of cells in apoptosis difficult. However,
Pcsk9−/− stromal regions exhibited a stronger labeling than WT ones,
whereas non-injected liver sections only showed a background signal.
In summary, these data suggest that the absence of PCSK9 causes
higher apoptosis in hepatic stromal and tumoral cells. The increased
apoptosis observed in tumors is probably indirect, as incubation of
B16F1 cells with PCSK9 failed to change their caspase-3 activity.
TNFα Pathway Is Affected in Pcsk9−/− Liver
To identify the underlying molecular pathway that promotes
apoptosis in the absence of PCSK9, we performed a qPCR array
analysis of 84 key genes involved in apoptosis on WT and Pcsk9−/−
liver stroma tissues that were collected 12 days after B16F1 cell injec-
tion. A set of genes was dysregulated in Pcsk9−/− mice (Table W1),
and the expression of selected genes was validated by qPCR in non-
injected livers, hepatic tumors, and stroma samples (Figure 6). The
most upregulated gene encodes TNFα, an inflammatory cytokine.
qPCR analysis confirmed that TNFα expression was 50% higher in
Pcsk9−/− stromal samples than inWT samples (Figure 6). Pcsk9−/− versus
WT non-injected livers also showed a trend for higher TNFα expres-
sion, but TNFα expression was similar in WT and Pcsk9−/− tumors.
To better assess the role of PCSK9 in TNFα gene regulation, we
took advantage of our transgenic mice, Tg(Apoe-PCSK9), in which
the apoE promoter drives the expression of PCSK9 essentially in the
liver and macrophages [11]. First, Tg(Apoe-PCSK9) livers expressed
38% less TNFα than Pcsk9−/− livers (Figure W4). Second, naïve peri-
toneal macrophages express >200-fold higher levels of TNFα than
liver. When isolated from Pcsk9−/− mice, their TNFα expression was
70% and 130% higher than in macrophages isolated from WT and
Tg(Apoe-PCSK9), respectively (Figure W4). Thus, these data confirm
Figure 5. PCSK9 affects cell proliferation and apoptosis of hepatic cells but not those of B16F1 cells. (A) Proliferation of B16F1 cells
incubated with or without 5 μg/ml of purified PCSK9, and grown in media containing 10% FBS, was measured using an MTS assay.
(B) B16F1 cells stably expressing the empty pIRES2-EGFP vector (pIR), V5-tagged human PCSK9 (PCSK9), or its variant PCSK9D374Y
(D347Y) were grown in media containing 10% FBS or 10% LPDS and their proliferation was measured. PCSK9 expression in these cell
lines was assessed by Western blot analysis of serum-free media using a V5 Ab (inset). (C) HepG2 cells stably expressing NTsh, PC9sh,
or human PCSK9 were grown in media containing 10% FBS and their proliferation was measured. PCSK9 expression and efficiency of
PCSK9 knockdown in these cell lines were assessed by Western blot analysis of serum-free media using a V5 Ab (inset). (D) Caspase-3
activity was measured in HepG2 cells stably expressing NTsh and PC9sh, WT and Pcsk9−/− primary hepatocytes, and B16F1 cells pre-
incubated with or without 5 μg/ml of purified PCSK9 for 24 hours, either in the absence or presence of 1 μM staurosporine. (E) Caspase-3
activity was assessed in non-injected liver extracts and in liver stroma and tumor extracts obtained from mice 12 days post–B16F1 cell
injection. Liver sections from both non-injected and B16F1 cell–injected WT and Pcsk9−/−mice were submitted to a TUNEL assay. Arrows
point at labeled apoptotic nuclei and dashed lines separate tumoral (T) and stromal (S) areas. The error bars indicate SEM of three inde-
pendent experiments (A–D) or data for six mice per genotype (E). *P < .05, **P < .01, ***P < .001 (Student’s t test).
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the existence of an inverse correlation between PCSK9 and TNFα
expression levels.
The expression of TNFR1 (gene Tnfsfr1a) was similar in WT and
Pcsk9−/− intact livers. However, injection of B16F1 cells significantly
induced TNFR1 expression by 50% and 110% in WT and Pcsk9−/−
liver stroma tissues, respectively, resulting in a 40% higher expression
of TNFR1 in the Pcsk9−/− stroma (Figure 6). Like TNFα, TNFR1 is
similarly expressed in liver tumors developed in WT or Pcsk9−/−
mice. Thus, the 40% higher expression of TNFR1 in the Pcsk9−/−
stroma should potentiate TNFα signaling in this tissue.
The binding of TNFα to TNFR1 can simultaneously elicit apop-
totic and nuclear factor κB (NF-κB)–mediated cell survival signals
[28]. NF-κB negatively regulates apoptosis by inducing the expres-
sion of anti-apoptotic factors [29], including Bcl-2 [30] and the
TRAF2, whose deficiency was shown to increase cell sensitivity to
TNFα-induced apoptosis [31,32] (Figure 6, lower right panel ).
Expression of both TRAF2 and Bcl-2 was 30% lower in Pcsk9−/− liver
stroma than in WT ones (Figure 6). In addition, Bcl-2 was down-
regulated by 20% in Pcsk9−/− tumors compared to WT ones. This sug-
gests that the absence of PCSK9 reduces the NF-κB survival response
and thus further increases cell susceptibility to apoptosis.
We then verified whether TNFα up-regulation depended on the
LDLR. Mice lacking the LDLR (Ldlr−/−) or both the LDLR and
PCSK9 (Ldlr−/−Pcsk9−/−, dKO) [11] and that exhibit similar high
plasma TC levels were analyzed before or after B16F1 cell injection.
The higher TNFα expression associated with the lack of PCSK9 was
conserved in the LDLR-deficient background. TNFα mRNA levels
were 90% higher in stroma (Figure 6, lower middle panel ), showing
that TNFα up-regulation does not depend on the LDLR.
In summary, these data indicate that, in an LDLR-independent
manner, PCSK9 deficiency leads to a stronger TNFα pro-apoptotic
signaling in liver stroma. In addition, Pcsk9−/− stroma and tumor exhib-
ited a reduced NF-κB pro-survival response that likely reinforces apop-
tosis in these tissues.
Circulating TNFα and PCSK9 Are Co-regulated in the
Course of Metastasis Progression
To confirm that the up-regulation of TNFα expression led to a
higher TNFα secretion, we measured the plasma levels of TNFα
by ELISA before injection and 2 and 12 days post–B16F1 cell injec-
tion. At all times, TNFα levels were about two-fold higher in Pcsk9−/−
plasma than inWT plasma (Figure 7A). In addition, in both genotypes,
Figure 6. TNFα pathway is altered in Pcsk9−/− mice. Expression of TNFα, TNFR1, TRAF2, and Bcl-2 was analyzed by qPCR in non-
injected livers (n = 9/genotype) and in liver stroma and tumors (n = 5–7/genotype) collected from mice 12 days post-injection. TNFα
expression was also assessed in non-injected livers (n = 12/genotype) and in liver stroma and tumors (n = 5/genotype) collected from
Ldlr−/− and Ldlr−/−Pcsk9−/− (dKO) mice (hatched bars). Error bars indicate SEM. *P < .05; **P < .01 (Student’s t test). In the lower right
panel, a scheme of the TNFα signaling pathway is shown. Binding of TNFα to TNFR1 triggers intracellular recruitment of TNF receptor–
associated death domain to TNFR1, which provides an assembly platform for TRAF2 and Fas-associated protein with a death domain
(FADD). The binding of TRAF2 leads to NF-κB activation that induces the transcription of survival and anti-apoptotic proteins, including
Bcl-2 and TRAF2. The binding of FADD leads to caspase activation and apoptosis. The events regulated by the absence of PCSK9 are
indicated by open arrows.
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TNFα levels increased with time, reaching four-fold higher levels at
12 days post-injection. In the same WT plasma samples, circulating
PCSK9 increased by 1.8-fold at 12 days post-injection, whereas
cholesterol levels were unaffected (Figure 7B). In agreement, we con-
firmed by qPCR that PCSK9 transcripts were 2.3-fold higher in stroma
than in non-injected livers, whereas LDLR transcripts were unchanged
(Figure 7C ). This suggests that the increases in TNFα and PCSK9
were independent of cholesterol [33].
Discussion
In this study, we investigated the role of PCSK9 in liver metastasis
formation, following B16F1 cells injection in the spleen of WT and
Pcsk9−/− mice. Because B16F1 cells and their derived tumors do not
express PCSK9 and exhibit LDLR levels that are insensitive to exog-
enous PCSK9, we exclusively examined the role of the host PCSK9
in metastasis development. First, we showed that PCSK9 enhances
liver metastasis development through its role in maintaining high cir-
culating cholesterol levels, as 1) an HCD that brought back the low
cholesterol levels of Pcsk9−/− mice to WT levels resulted in increased
metastasis in Pcsk9−/− mice and 2) an extended HCD enhanced
liver metastasis development in both genotypes. Second, we showed
that PCSK9 protects HepG2 cells, primary hepatocytes, and liver
stroma and metastases against apoptosis, at least in part by main-
taining low levels of TNFα expression in an LDLR/cholesterol-
independent manner.
Tumor development depends on the reciprocal interaction of the
tumor with its microenvironment. Locally activated stromal cells
modify the proliferative and invasive behavior of cancer cells [34].
Diminished liver metastases in Pcsk9−/− mice revealed that the lack of
PCSK9 generates a less permissive environment for tumor expansion.
First, tumor cell proliferation may be indirectly limited in Pcsk9−/−
mice, as the proliferation of B16F1 cells in vitro strongly depends on
cholesterol. Second, increased apoptosis in liver stroma and metastases
may contribute to lower metastasis in Pcsk9−/− mice. However, the
relative contributions of lower proliferation versus higher apoptosis to
the Pcsk9−/− protective phenotype remain to be determined.
PCSK9was originally named “neural apoptosis-regulated candidate-1”
because of its up-regulation upon induction of apoptosis by serum
withdrawal [35]. Since then, the implication of PCSK9 in apoptosis
has been frequently evoked. In hepatic cells and tissues, PCSK9 seems
to be anti-apoptotic. A microarray study showed that overexpression of
the gain-of-function PCSK9D347Y downregulates some pro-apoptotic
genes in HepG2 cells [10]. Additionally, the lack of PCSK9 enhances
apoptosis during liver regeneration [11]. In contrast, an in vitro study
revealed that PCSK9 has a pro-apoptotic effect in primary cultures of
cerebellar granular neurons through its ability to degrade the apolipo-
protein receptor 2 [36]. However, unlike neuronal primary cultures,
liver expresses very low levels of this receptor. Thus, the present study
constitutes the first in vivo evidence that PCSK9 has an anti-apoptotic
effect in the mouse liver.
What are the underlying mechanisms of the anti-apoptotic prop-
erties of PCSK9? Surprisingly, even though PCSK9 had no effect on
B16F1 cell apoptosis, B16F1 cell–derived tumors exhibited higher
caspase-3 activities, suggesting apoptosis was initiated by a stromal
apoptotic factor. TNFα is a good candidate. It was upregulated in
liver stroma but not in tumors. It was also two-fold higher in
Pcsk9−/− plasma. Furthermore, TNFα is a potent anti-cancer agent
used to treat advanced soft-tissue sarcomas and melanoma, because
of its ability to induce tumor cell apoptosis [37,38]. Although TNFα
can also activate NF-κB–mediated cell survival responses, NF-κB
signaling was rather reduced in Pcsk9−/− stroma, as lower mRNA
levels of its downstream targets Bcl-2 and TRAF2 were measured.
Finally, the modest, but significant, TNFα up-regulation observed
was independent of 1) circulating cholesterol levels, which remained
unchanged during metastasis development, or 2) LDLR, as the same
TNFα increase was observed in mice lacking both PCSK9 and
LDLR and exhibiting hypercholesterolemia (∼300 mg/dl TC).
One of the objectives of this work was to assess the safety of
PCSK9 inhibition, which may be widely used to control hyper-
cholesterolemia. Unlike the clear association between hypercho-
lesterolemia and elevated risk of cardiovascular diseases [4], the
relation between cholesterol and cancer remains unclear. This is
mainly due to the high heterogeneity of this disease. Cholesterol
levels have been positively correlated with cancers of brain [39], colon
[40], and prostate [41], suggesting that cholesterol-lowering drugs
could be beneficial to manage the progression of these cancers. For
instance, statins that inhibit cholesterol synthesis have been proven to
Figure 7. Plasma TNFα and PCSK9 are upregulated along metastasis formation. (A) TNFαwas measured before injection and 2 and 12 days
post-injection in the plasma of WT and Pcsk9−/− mice (n = 12/genotype). (B) Circulating PCSK9 and plasma TC were measured before
injection and 2 and 12 days post-injection in WT mice (n = 12). (C) PCSK9 and LDLR expression levels were measured by qPCR in non-
injected livers and inB16F1 cell–injected livers (stroma) fromWTmice (n=5). The data are representedby themeans±SEM. *P< .05; **P<
.01; ***P < .001 (Student’s t test).
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be effective to limit the growth and progression of prostate cancer
[42,43]. In contrast, cholesterol levels have been negatively cor-
related with cancers of breast [39], lung [40], and liver [44,45].
However, the latter correlation is confounded by a preclinical effect,
in which plasma cholesterol declines before the diagnosis of cancer
[46]. Furthermore, although a negative correlation between the risk
of primary liver cancer and cholesterol has been shown in humans
[44,45], a mouse study demonstrated that lower plasma cholesterol
levels, achieved by a cholesterol synthesis inhibitor, significantly reduced
liver metastasis [47]. In agreement with the latter study, the present
work that monitored liver metastasis progression, but not primary liver
cancer, strongly suggests an adverse role of cholesterol. Thus, future
PCSK9 inhibitors that lower LDLc [8] may also be beneficial to control
hepatic metastasis progression.
The beneficial effect of PCSK9 deficiency resides 1) in its asso-
ciated hypocholesterolemia that may decrease B16F1 cell growth
and 2) in increased cell apoptosis, likely due to chronically elevated
levels of TNFα. Even though this work was focused on melanoma, it
suggests that a PCSK9 inhibitor, initially developed to treat hyper-
cholesterolemia [8], may be useful in therapies directed against mela-
noma and possibly other types of cancer metastasis.
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Figure W1. Tyrosinase expression in liver tumor and stroma. The
absence of contamination of the liver stroma samples by tumoral
cells was verified by assessing tyrosinase expression by qPCR in
these samples (n = 12). Tyrosinase is implicated in the synthesis
of the melanin pigment that is abundantly produced by tumoral
cells. The primers used for the amplification of tyrosinase cDNA
were given as follows: forward, 5′-CACAGGCACCTATGGCCAAAT-
GAAC; reverse, 5′-CCAGTATGGAACAGTGAAGTTCTCATC. Error
bars indicate SEM.
Figure W3. PC expression in B16F1 cells. Mouse furin, PC5/6,
PACE4, PC7, PCSK9, and SKI-1 expression were quantified by
qPCR in B16F1 cells (n = 3) and B16F1 cell–derived liver tumors
(n = 3). The primers used to amplify these cDNA were reported
previously [18].
Figure W2. Expression of PCSK9 in various cancers. Data sets were retrieved from ONCOMINE (a cancer microarray database and
integrated data mining platform) with a threshold of P < .0001. PCSK9 expression value in tumors was log2 transformed and normalized
by that in the adjacent normal tissue. Cancers in which PCSK9 was upregulated or downregulated are listed in red or blue, respectively.
Table W1. (continued )
Genes GenBank Fold Change KO/WT
Traf1 NM_009421 0.68
Traf2 NM_009422 0.65
Cradd NM_009950 0.63
Birc5 NM_009689 0.62
Il10 NM_010548 0.55
Tnfsf10 NM_009425 0.54
Dsip1 NM_010286 0.51
Pycard NM_023258 0.48
Bcl2 NM_009741 0.43
Trp53 NM_011640 0.41
Hells NM_008234 0.24
Trp53inp1 NM_021897 0.20
Bcl2l10 NM_013479 No C t
Casp14 NM_009809 No C t
Cidea NM_007702 No C t
Lhx4 NM_010712 No C t
Pak7 NM_172858 No C t
Tnfsf5 NM_011616 No C t
Tnfsf7 NM_011617 No C t
Trp63 NM_011641 No C t
Trp73 NM_011642 No C t
Table W1. Comparative Expression of 84 Key Genes Associated with Apoptosis in WT and Pcsk9−/−
Liver Stroma.
Genes GenBank Fold Change KO/WT
Tnf NM_013693 5.28
Bak1 NM_007523 2.27
Nme5 NM_080637 2.01
Tnfrsf1a NM_011609 1.96
Bcl10 NM_009740 1.46
Fas NM_007987 1.41
Dffa NM_010044 1.40
Tnfrsf11b NM_008764 1.35
Sphk2 NM_147325 1.35
Zc3hc1 NM_172735 1.34
Casp4 NM_007609 1.31
Fasl NM_010177 1.31
Birc1a NM_008670 1.31
Ripk1 NM_009068 1.30
casp2 NM_007610 1.28
Polb NM_011130 1.27
Nol3 NM_030152 1.24
Birc2 NM_007465 1.24
Card6 XM_139295 1.20
Bnip3 NM_009760 1.13
Casp6 NM_009811 1.13
Card4 NM_172729 1.13
Dffb NM_007859 1.12
Prdx2 NM_011563 1.09
Bad NM_007522 1.07
Bnip3l NM_009761 1.06
Tnfsf12 NM_011614 1.05
Tnfrsf5 NM_011611 1.05
Traf3 NM_011632 1.05
Bmip2 NM_016787 1.04
Mcl1 NM_008562 1.03
Card10 NM_130859 1.03
Fadd NM_010175 1.01
Casp9 NM_015733 1.00
Birc4 NM_009688 0.99
Dab1 NM_010015 0.98
Apaf1 NM_009684 0.98
Dapk1 NM_029653 0.98
Bcl2l2 NM_007537 0.97
Casp8 NM_009812 0.97
Bax NM_007527 0.96
Cflar NM_009805 0.95
Rnf7 NM_135065 0.95
Ltbr NM_010736 0.95
Pim2 NM_145737 0.91
Tnfrsf10b NM_020275 0.91
Bid NM_007544 0.89
Birc3 NM_007464 0.88
Birc1b NM_010872 0.88
Bag1 NM_009736 0.87
Casp12 NM_009808 0.86
Api5 NM_007466 0.85
Nfkb1 NM_008689 0.83
Bag3 NM_013863 0.81
Bok NM_016778 0.81
Akt1 NM_009652 0.78
Bcl2l1 NM_009743 0.77
Casp7 NM_007611 0.76
Casp1 NM_009807 0.74
Trp53bp2 NM_173378 0.73
Atf5 NM_030693 0.72
Cideb NM_009894 0.72
Casp3 NM_009810 0.71
Figure W4. TNFα expression in livers and naïve macrophages.
TNFα and PCSK9 expression was analyzed by qPCR in non-injected
livers and naïve macrophages isolated from WT, Pcsk9−/−, and
PCSK9 transgenic (Tg) [11] mice (n = 6–10/genotype). Naïve
macrophages were isolated from the mouse peritoneal cavity by
lavaging with 10 ml of PBS. After centrifugation at low speed,
the cell pellet was washed twice with 10ml of PBS. Cells were then
allowed to adhere to a plastic culture dish (35 mm) for 3 hours in
RPMI 1640 containing 10% FBS. Non-adherent cells were washed
off and adherent cells (essentially macrophages) were harvested for
RNA extraction. Error bars indicate SEM. *P < .05 (Student’s t test).
